Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs

Glycomine’s lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission. The post Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare…

Read More

Debunked Episode 13: Will the Real AI Please Stand Up?

The latest episode of Debunked, with MedCity News Editor in Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch, talked about the many iterations of AI, NIH funding cuts, and a deal to sell Walgreens. The post Debunked Episode 13: Will the Real AI Please Stand Up? appeared first on MedCity News.

Read More